Exit Strategies for Biologic Therapy in IBD: Is It Too Soon to Stop?
Open Access
- 14 March 2018
- journal article
- editorial
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (4) , 669-670
Abstract
The advent of biologic therapies, in particular tumor necrosis factor–alpha (TNFα) blockers, has resulted in a major change in the way Crohn’s disease and ulcerative colitis are managed. This has been, in part, due to the demonstrated efficacy of these agents both for induction therapy for patients with symptoms or complications that are due to active inflammatory disease and for maintenance therapy in those patients who have responded to induction therapy.1–5 In addition, there is evidence that these drugs can result in mucosal healing, which, in turn, has been associated with improved long-term outcomes such as reduced hospitalization and reduced surgery.6–9 When these drugs were first introduced approximately 18 years ago, there was hope that they could be used for short-term therapy to induce remission, and that remission would then be maintained with other more conventional therapies or that the biologic drugs could be used intermittently in an “on demand” basis for flares of inflammatory disease activity. Unfortunately, these strategies have proven ineffective and have been associated with significant risk of clinical disease relapse following drug discontinuation and high rates of antidrug antibody development.10–12 As a result, there has been a tendency to maintain patients who respond to anti-TNF therapy on treatment indefinitely. However, despite the comparatively good short- and long-term safety profile of anti-TNF biologics, there has been a persisting concern among many patients and some physicians regarding the cumulative risk of therapy extended over many years or even decades.13–15 Aside from potential long-term safety concerns, there is the additional consideration of the financial impact of biologic therapy. Compared with nonbiologic therapies used to manage IBD, biologic therapy is very expensive. Medication costs currently account for an increasingly large portion of the overall cost of treating IBD, and the cost of medications appears to have replace surgery and hospitalizations as the largest single driver of cost. As a result, there are both individual and societal cost pressures that dictate that we should reexamine the indefinite use of these drugs in IBD patients to determine if similar improvements in outcomes can be achieved with other less costly, and possibly safer, approaches to the use of biologic therapies.Keywords
This publication has 17 references indexed in Scilit:
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative ColitisGastroenterology, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s diseaseGastroenterology, 2005
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999